RxDoctor Payments Data

Benjamin Scott

Family · Greencastle, INNPI 1144717000

Payments from drug & device makers

$1,734in general payments, 2019–2025

Across 94 payments — averaging $18.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$453
  • Lilly USA, LLC$246
  • Corium, LLC$222
  • Novo Nordisk$201
  • AstraZeneca$180
  • GSK$91
  • plus $341 from 11 others

What the payments were for

  • Food & beverage$1,734100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,734 in reported general payments places this provider in the 75th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$97,873
Medicare patients
23
Services billed
123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TasignaNilotinib Hcl13$133,016
EliquisApixaban97$94,610
JanuviaSitagliptin Phosphate63$75,454
FarxigaDapagliflozin Propanediol100$71,742
OzempicSemaglutide46$67,326
JardianceEmpagliflozin45$54,869
TrulicityDulaglutide30$44,613
MounjaroTirzepatide35$37,852
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$37,528
Breztri AerosphereBudesonide/Glycopyr/Formoterol35$21,206
XareltoRivaroxaban27$18,154
Breo ElliptaFluticasone/Vilanterol20$17,371
Janumet XrSitagliptin Phos/Metformin Hcl11$16,641
MyrbetriqMirabegron26$14,398
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$12,985

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisTasigna$30$133,01613 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$180$100,640157 claims
Lilly USA, LLCTrulicity, Mounjaro$246$82,46565 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$91$67,88495 claims
Novo NordiskOzempic$201$67,32646 claims
Boehringer IngelheimJardiance, Stiolto Respimat$53$64,75260 claims
AbbVieLinzess$453$11,69819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,392 family providers in Indiana.

Other family in Greencastle

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →